JP2011182748A - Feed for livestock or poultry - Google Patents
Feed for livestock or poultry Download PDFInfo
- Publication number
- JP2011182748A JP2011182748A JP2010053646A JP2010053646A JP2011182748A JP 2011182748 A JP2011182748 A JP 2011182748A JP 2010053646 A JP2010053646 A JP 2010053646A JP 2010053646 A JP2010053646 A JP 2010053646A JP 2011182748 A JP2011182748 A JP 2011182748A
- Authority
- JP
- Japan
- Prior art keywords
- feed
- livestock
- poultry
- coenzyme
- antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000144972 livestock Species 0.000 title claims abstract description 66
- 244000144977 poultry Species 0.000 title claims abstract description 63
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 106
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 47
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 45
- 230000000968 intestinal effect Effects 0.000 claims abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 50
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 9
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 239000003674 animal food additive Substances 0.000 abstract description 8
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 239000004599 antimicrobial Substances 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 235000013594 poultry meat Nutrition 0.000 description 45
- 241000894006 Bacteria Species 0.000 description 20
- -1 ibrosin Chemical compound 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- OLOCXIJVDIVAHH-FXRZFVDSSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN1CCCN=C1\C=C\C1=C(C)C=CS1 OLOCXIJVDIVAHH-FXRZFVDSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229960003683 amprolium Drugs 0.000 description 2
- 229960001127 colistin sulfate Drugs 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- PJBQYZZKGNOKNJ-UHFFFAOYSA-M hydron;5-[(2-methylpyridin-1-ium-1-yl)methyl]-2-propylpyrimidin-4-amine;dichloride Chemical compound Cl.[Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C PJBQYZZKGNOKNJ-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 235000013613 poultry product Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- XOIQMTLWECTKJL-FBZUZRIGSA-M sodium;(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C([O-])=O)O2 XOIQMTLWECTKJL-FBZUZRIGSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- GRRNUXAQVGOGFE-SVNOMHMPSA-N (3'r,3as,4s,4's,5'r,6r,6'r,7s,7as)-4-[(1s,2r,3s,5r,6s)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1s)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol Chemical compound O[C@H]1[C@H](NC)C[C@H](N)[C@@H](O)[C@@H]1O[C@H]1[C@H]2OC3([C@@H]([C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-SVNOMHMPSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- NBOODGNJLRRJNA-IAGPQMRQSA-N 2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl Chemical compound OP(O)(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 NBOODGNJLRRJNA-IAGPQMRQSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- WGLYHYWDYPSNPF-RQFIXDHTSA-N Apramycin sulfate Chemical compound OS(O)(=O)=O.O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O WGLYHYWDYPSNPF-RQFIXDHTSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 description 1
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 description 1
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- WOUDXEYYJPOSNE-VKZDFBPFSA-N bicozamycin Chemical compound N1C(=O)[C@@]2(O)NC(=O)[C@]1([C@@H](O)[C@@](O)(CO)C)OCCC2=C WOUDXEYYJPOSNE-VKZDFBPFSA-N 0.000 description 1
- 229950007558 bicozamycin Drugs 0.000 description 1
- WOUDXEYYJPOSNE-UHFFFAOYSA-N bicyclomycin Natural products N1C(=O)C2(O)NC(=O)C1(C(O)C(O)(CO)C)OCCC2=C WOUDXEYYJPOSNE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- FDSDTBUPSURDBL-DKLMTRRASA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-DKLMTRRASA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 229960001878 decoquinate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002416 diarrheagenic effect Effects 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- NJCUSQKMYNTYOW-MWUYRYRWSA-N enramicina Chemical compound O.N1C(=O)NC(=O)C(C=2C=C(Cl)C(O)=C(Cl)C=2)NC(=O)C(CO)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(CC2N=C(N)NC2)NC(=O)C(CCCNC(N)=O)NC(=O)C(C(C)O)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C(C)O)NC(=O)N(CCCCN)C(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)/C=C/C=C/CCCCC(C)CC)C(C)OC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C)NC(=O)C1CC1CNC(N)=N1 NJCUSQKMYNTYOW-MWUYRYRWSA-N 0.000 description 1
- 229950003984 enramycin Drugs 0.000 description 1
- 108700041171 enramycin Proteins 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960001851 narasin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229960002796 polystyrene sulfonate Drugs 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- ITCAUAYQCALGGV-UHFFFAOYSA-M sodium;1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound [Na+].C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C([O-])=O ITCAUAYQCALGGV-UHFFFAOYSA-M 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960003097 sulfaquinoxaline Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940031989 tylosin phosphate Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
Description
本発明は、補酵素Ｑを含有する家畜又は家禽用飼料、当該飼料を利用する家畜又は家禽の生産方法、及び、その方法により得られる家畜又は家禽に関する。 The present invention relates to a livestock or poultry feed containing coenzyme Q, a livestock or poultry production method using the feed, and a livestock or poultry obtained by the method.
家畜・家禽の疾病を予防し、成長を促進するために抗生物質及び抗菌剤を家畜又は家禽用飼料に添加することは広く行われてきた。抗生物質及び抗菌剤による成長促進作用の有力なメカニズムとして、腸内の有害細菌の増殖を抑制し、腸内環境を整えることが考えられる。一方、抗生物質及び抗菌剤を家畜又は家禽飼料に使用することは、抗生物質及び抗菌剤を広く環境中にばらまくことになり、結果として抗生物質及び抗菌剤に対する耐性菌の出現を誘発することが社会的に問題となっている。また、抗生物質及び抗菌剤を使用しない、あるいは使用量を極力抑えた安心・安全な家畜及び家禽生産物に対する社会的要望が年々高まってきている。 The addition of antibiotics and antibacterial agents to livestock or poultry feeds has been widely practiced to prevent livestock and poultry diseases and promote growth. As a promising mechanism of the growth promoting action by antibiotics and antibacterial agents, it is conceivable to suppress the proliferation of harmful bacteria in the intestine and to prepare the intestinal environment. On the other hand, the use of antibiotics and antibacterial agents in livestock or poultry feed will cause the antibiotics and antibacterial agents to spread widely in the environment, resulting in the appearance of resistant bacteria to antibiotics and antibacterial agents. It is a social problem. In addition, social demands for safe and safe livestock and poultry products that do not use antibiotics and antibacterial agents or minimize the amount used are increasing year by year.
抗生物質及び抗菌剤を使用することなく家畜または家禽の細菌性感染症を予防する方法として、有機酸を家畜又は家禽飼料に添加することが特許文献１、及び、特許文献２に記載されている。しかし、有機酸による細菌性感染症予防効果を発揮させるためには、飼料に対して有機酸を多量に添加することが必要であり、さらに有機酸の使用は家畜又は家禽の嗜好性低下を引き起こしたり、給餌設備を腐食させたりする問題がある。また、ＳＰＦ豚（腸内に棲息する細菌の多くが善玉菌で、悪玉菌が少ない）のように、施設面及び管理技術面で特別の配慮を施した清潔な環境で家畜や家禽を飼育する方法も考えられるが、設備取得・維持管理と衛生管理面で高額の費用を要する問題がある。 Patent Document 1 and Patent Document 2 describe that an organic acid is added to livestock or poultry feed as a method for preventing bacterial infections of livestock or poultry without using antibiotics and antibacterial agents. . However, in order to exert the effect of preventing bacterial infection caused by organic acids, it is necessary to add a large amount of organic acids to the feed, and the use of organic acids causes a decrease in the preference of livestock or poultry. Or corroding the feeding equipment. Raise livestock and poultry in a clean environment with special considerations in terms of facilities and management techniques, such as SPF pigs (most of the bacteria that inhabit the intestines are good bacteria and few bad bacteria) Although a method is conceivable, there is a problem that requires high costs in terms of equipment acquisition / maintenance management and hygiene management.
飼料添加剤として通常使用されている抗生物質及び抗菌剤を添加することなく、あるいはその使用量を軽減し、家畜または家禽の良好な成長を確保できる家畜又は家禽用飼料を提供することを課題とした。 An object of the present invention is to provide livestock or poultry feed that can ensure good growth of livestock or poultry without adding or reducing the amount of antibiotics and antibacterial agents normally used as feed additives. did.
本発明者らは上記課題を解決すべく、鋭意、研究を重ね、飼料添加剤として指定されている抗生物質及び抗菌剤を全く含まないか、通常使用される濃度よりも低濃度の抗生物質及び抗菌剤を含み、かつ補酵素Ｑを含む家畜又は家禽用飼料が、通常使用される濃度の抗生物質及び抗菌剤を含む飼料と同等の腸内細菌叢改善作用及び飼料効率向上作用を有することを見出し、本発明を完成するに至った。 In order to solve the above problems, the present inventors have intensively and researched and do not include antibiotics and antibacterial agents designated as feed additives at all, or antibiotics having a concentration lower than that normally used, and The feed for livestock or poultry containing an antibacterial agent and containing coenzyme Q has an intestinal microbiota improving effect and a feed efficiency improving effect equivalent to those of a feed containing antibiotics and antibacterial agents at concentrations usually used. The headline and the present invention were completed.
すなわち、本発明は、抗生物質の含有量及び抗菌剤の含有量の合計が８０ｐｐｍ未満で、かつ、下記式（１）で表される補酵素Ｑ、及び、下記式（２）で表される補酵素Ｑから選択される少なくとも一つを含有する、家畜又は家禽用飼料に関する。
抗生物質及び抗菌剤を全く含有しないことが好ましい。 Preferably no antibiotics or antibacterials are contained.
補酵素Ｑの含有量が抗生物質の含有量及び抗菌剤の含有量の合計３重量部に対して２重量部以上であることが好ましい。 It is preferable that the content of coenzyme Q is 2 parts by weight or more with respect to 3 parts by weight in total of the content of antibiotics and the content of antibacterial agents.
補酵素Ｑを１ｐｐｍ以上含有することが好ましい。 It is preferable to contain 1 ppm or more of coenzyme Q.
補酵素Ｑが補酵素Ｑ１０であることが好ましい。 The coenzyme Q is preferably coenzyme Q10.
さらに、本発明は、上記飼料を家畜又は家禽に給餌することを特徴とする腸内細菌叢の改善方法に関する。 Furthermore, the present invention relates to a method for improving the intestinal microflora characterized by feeding the above feed to livestock or poultry.
さらに、本発明は、上記飼料を家畜又は家禽に給餌することを特徴とする家畜又は家禽の生産方法に関する。 Furthermore, the present invention relates to a method for producing livestock or poultry, characterized in that the feed is fed to livestock or poultry.
上記飼料を、飼料への抗生物質及び抗菌剤の添加が認められている期間に家畜又は家禽に給餌することが好ましい。 It is preferable to feed the above feed to livestock or poultry during a period when the addition of antibiotics and antibacterial agents to the feed is permitted.
上記飼料を、飼料への抗生物質及び抗菌剤の添加が禁止されている期間に家畜又は家禽に給餌することが好ましい。 It is preferable to feed the feed to livestock or poultry during a period when the addition of antibiotics and antibacterial agents to the feed is prohibited.
さらに、本発明は、上記生産方法により生産される、牛、豚または鶏に関する。 Furthermore, this invention relates to the cow, pig, or chicken produced by the said production method.
本発明により家畜又は家禽の飼養において既存の飼料添加物である抗生物質及び抗菌剤やＳＰＦ施設を用いることなく、家畜や家禽の腸内環境を整えて健康に飼養すること及び飼料効率を向上させることが可能になる。また、抗生物質及び抗菌剤の飼料添加物としての使用は、産卵鶏については産卵中、豚では体重７０ｋｇ以上出荷までの期間、肉用鶏及び肉用牛ではと殺前７日間、乳牛では搾乳中は使用が禁止されており、さらに動物薬としての治療目的の使用は、薬剤の種類、対象の家畜・家禽の種類によって異なるが、例えば、硫酸ゲンタマイシンを肉用牛に使用する場合はと殺前３０日間、硫酸アプラマイシンを豚に使用する場合はと殺前１４日間、チアンフェニコールを肉用鶏に使用する場合はと殺前１４日間、それぞれ使用が禁止されている。このような抗生物質・抗菌剤が使用できない期間、家畜や家禽は細菌感染のリスクにさらされることになるが、本発明の飼料によりそのリスクを低減可能となる。さらに、本発明は抗生物質及び抗菌剤のような耐性菌の発現の恐れがなく、安心・安全な家畜及び家禽生産物の生産に多大の貢献をなすものである。 According to the present invention, in the breeding of livestock or poultry, the existing feed additives such as antibiotics and antibacterial agents and SPF facilities are used, and the intestinal environment of livestock and poultry is maintained and kept healthy and feed efficiency is improved. It becomes possible. The use of antibiotics and antibacterial agents as feed additives is as follows: during laying for laying hens, period up to 70 kg body weight for pigs, 7 days before killing for hens and beef cattle, milking for dairy cows However, the use for therapeutic purposes as veterinary drugs varies depending on the type of drug and the target livestock and poultry, but for example, when gentamicin sulfate is used for beef cattle The use of apramycin sulfate for pigs is prohibited for 30 days before and 14 days before killing, and thiaphenicol is used for meat chickens for 14 days before killing. During the period when such antibiotics and antibacterial agents cannot be used, livestock and poultry are exposed to the risk of bacterial infection, but the risk can be reduced by the feed of the present invention. Furthermore, the present invention does not fear the development of resistant bacteria such as antibiotics and antibacterial agents, and greatly contributes to the production of safe and safe livestock and poultry products.
本発明の家畜又は家禽用飼料は、抗生物質の含有量及び抗菌剤の含有量の合計が８０ｐｐｍ未満で、かつ、下記式（１）で表される補酵素Ｑ、及び、下記式（２）で表される補酵素Ｑから選択される少なくとも一つを含有する。 The feed for livestock or poultry of the present invention has a total content of antibiotics and antibacterial agents of less than 80 ppm, and coenzyme Q represented by the following formula (1) and the following formula (2) At least one selected from coenzyme Q represented by the formula:
本発明で使用する補酵素Ｑは、動植物中に広く存在することが知られている。上記式（１）及び式（２）で表される補酵素Ｑのうち、本発明においては、ｎが６〜１１のいずれかであるもの、あるいはそれらの混合物であることが望ましい。特にｎが１０である補酵素Ｑ１０が好ましい。 It is known that coenzyme Q used in the present invention is widely present in animals and plants. Among the coenzymes Q represented by the above formulas (1) and (2), in the present invention, n is preferably any one of 6 to 11, or a mixture thereof. Particularly preferred is coenzyme Q10 in which n is 10.
また、補酵素Ｑは、化学合成品、発酵品、天然物からの抽出物など、形態を問わず使用することができる。例えば補酵素Ｑを含有する微生物（細菌、酵母など）そのもの、あるいはその粗精製物でもよく、また、これらから補酵素Ｑを精製したものでもよく、精製の程度も制限されない。最終的に飼料に混合される補酵素Ｑが一定量以上あればよい。また、ここでいう補酵素Ｑは、酸化型（上記式（１））、還元型（上記式（２））に限定されず、どちらか一方あるいはこれらの混合物であってもよい。また、それらの混合割合も制限されない。 Moreover, coenzyme Q can be used regardless of form, such as a chemically synthesized product, a fermented product, and an extract from a natural product. For example, the microorganism (cobacteria, yeast, etc.) itself containing coenzyme Q or a crude product thereof may be used, or a product obtained by purifying coenzyme Q therefrom, and the degree of purification is not limited. The coenzyme Q finally mixed in the feed may be a certain amount or more. The coenzyme Q here is not limited to the oxidized form (the above formula (1)) and the reduced form (the above formula (2)), and may be either one or a mixture thereof. Further, the mixing ratio thereof is not limited.
本発明の家畜又は家禽用飼料には、抗生物質や抗菌剤の代替効果を有する補酵素Ｑが含まれるため、抗生物質や抗菌剤の使用量を通常の使用量より低くすることができる。すなわち、本発明の家畜又は家禽用飼料は、補酵素Ｑを含有し、かつ抗生物質や抗菌剤を通常使用される量より少なく含有する、家畜又は家禽用飼料である。家畜又は家禽用飼料において、抗生物質及び抗菌剤の通常使用される濃度は、使用目的、対象動物、抗生物質・抗菌剤の種類などによって異なるが、例えば、オキシテトラサイクリンを感染症の治療を目的として使用する場合、豚・鶏用途で１００〜４００ｐｐｍ（力価）、子牛用途で２００〜４００ｐｐｍ（力価）であり、塩酸ドキシサイクリンであれば、豚用途でドキシサイクリンとして１００〜２００ｐｐｍ（力価）であり、モネンシンナトリウムであれば、鶏に使用する場合、８０ｐｐｍである。さらには複数の抗生物質や抗菌剤が併用されることもある。従って、本発明の家畜又は家禽用飼料に含まれる抗生物質や抗菌剤の含有量としては、これら通常使用される濃度より少なければ特に限定されないものの、例えば、抗生物質の含有量及び抗菌剤の含有量の合計がその力価として８０ｐｐｍ未満であるか、抗生物質及び抗菌剤が全く含まれなくてもよい。なお、抗生物質の含有量及び抗菌剤の含有量は、抗生物質及び抗菌剤の使用量を低減した上で、なおかつ家畜又は家禽の良好な成長を確保する観点から、それらの力価として４０ｐｐｍ未満が好ましく、３０ｐｐｍ未満がより好ましく、２０ｐｐｍ以下がさらに好ましく、１０ｐｐｍ以下が最も好ましい。特に、クエン酸モランテルを使用する場合はその含有量は３０ｐｐｍ未満であるのが好ましく、硫酸コリスチンまたはアビラマイシンを使用する場合にはその含有量は４０ｐｐｍ未満が好ましい。 Since the livestock or poultry feed of the present invention contains coenzyme Q having an effect of substituting antibiotics and antibacterial agents, the amount of antibiotics and antibacterial agents used can be made lower than the normal usage amount. That is, the livestock or poultry feed of the present invention is a livestock or poultry feed that contains coenzyme Q and contains less antibiotics and antibacterial agents than are normally used. In livestock or poultry feed, the concentrations of antibiotics and antibacterial agents that are normally used vary depending on the purpose of use, the target animal, the type of antibiotic / antibacterial agent, etc., but for example, oxytetracycline for the purpose of treating infectious diseases When used, it is 100 to 400 ppm (titer) for pig and chicken use, 200 to 400 ppm (titer) for calf use, and doxycycline hydrochloride is 100 to 200 ppm (titer) as doxycycline for pig use. Yes, monensin sodium is 80 ppm when used for chickens. In addition, multiple antibiotics and antibacterial agents may be used in combination. Accordingly, the content of antibiotics and antibacterial agents contained in the livestock or poultry feed of the present invention is not particularly limited as long as it is less than the concentration normally used. However, for example, the content of antibiotics and the content of antibacterial agents The total amount may be less than 80 ppm as its titer, or no antibiotics and antimicrobial agents may be included. In addition, the content of antibiotics and the content of antibacterial agents are less than 40 ppm as their titers from the viewpoint of reducing the amount of antibiotics and antibacterial agents used and ensuring good growth of livestock or poultry. Is preferable, less than 30 ppm is more preferable, 20 ppm or less is further preferable, and 10 ppm or less is most preferable. In particular, when using morantel citrate, the content is preferably less than 30 ppm, and when using colistin sulfate or aviramycin, the content is preferably less than 40 ppm.
ここで、抗生物質とは特に限定されるわけではないが、例えばドキシサイクリン、アイブロシン、亜鉛バシトラシン、アビラマイシン、オキシテトラサイクリン、エフロトマイシン、エンラマイシン、クロルテトラサイクリン、サリノマイシンナトリウム、セデカマイシン、センデュラマイシンナトリウム、デストマイシンＡ、ナラシン、ノシヘプタイド、バージニアマイシン、ビコザマイシン、フラボフォスフォリポール、モネンシンナトリウム、ラサロシドナトリウム、硫酸コリスチン、リン酸タイロシン、及び、その塩や誘導体が挙げられる。また、抗菌剤としては、特に限定されるわけではないが、例えばアンプロリウム・エトパベート、アンプロリウム・エトパベート・スルファキノキサリン、クエン酸モランテル、デコキネート、ナイカルバジン、ハロフジノンポリスチレンスルホン酸カルシウムが挙げられる。 Here, the antibiotic is not particularly limited, but for example, doxycycline, ibrosin, zinc bacitracin, aviramycin, oxytetracycline, ephromycin, enramycin, chlortetracycline, salinomycin sodium, cedecomycin, senduramycin Examples thereof include sodium, destomycin A, narasin, nociheptide, virginiamycin, bicozamycin, flavophospholipol, sodium monensin, rasaloside sodium, colistin sulfate, tylosin phosphate, and salts and derivatives thereof. In addition, the antibacterial agent is not particularly limited, and examples thereof include amprolium etopabate, amprolium etopate sulfaquinoxaline, morantel citrate, decoquinate, nicarbazine, and calcium halofuginone polystyrene sulfonate.
本発明において、補酵素Ｑは、抗生物質及び抗菌剤を全く含まない飼料または通常使用される濃度よりも低濃度の抗生物質及び抗菌剤を含む飼料に混ぜて与えられるが、紛体状態あるいは溶液状態で、他の通常の飼料とは分けて直接家畜又は家禽に投与してもよい。投与の簡便性から補酵素Ｑを飼料に混ぜる方法が好ましい。即ち、補酵素Ｑを飼料に添加することにより、飼料に添加する抗生物質及び抗菌剤の量を減らしつつ、抗生物質及び抗菌剤を通常の濃度で添加した時と同等の効果を維持することが可能となる。 In the present invention, coenzyme Q is given by mixing in a feed containing no antibiotics and antibacterial agents or in a feed containing antibiotics and antibacterial agents at concentrations lower than those normally used. Therefore, it may be administered directly to livestock or poultry separately from other normal feeds. A method of mixing coenzyme Q with the feed is preferable in terms of ease of administration. That is, by adding coenzyme Q to the feed, the amount of antibiotics and antibacterial agents added to the feed can be reduced while maintaining the same effect as when antibiotics and antibacterial agents were added at normal concentrations. It becomes possible.
飼料への補酵素Ｑの添加方法については、特に制限されるものではない。補酵素Ｑを直接飼料に添加混合してもよく、また、必要に応じて補酵素Ｑを飼料添加物と混合した上で飼料に添加して補酵素Ｑ含有飼料としてもよい。飼料添加物としては生菌剤（例えば、エンテロコッカス類、バチルス類、ビフィズス菌類）、抗酸化剤（例えば、エトキシン、ジブチルヒドキシトルエン等）、防かび剤（例えば、プロピオン酸、プロピオン酸カルシウム等）、粘結剤（例えば、アルギン酸ナトリウム、カゼインナトリウム、カルボキシメチルセルロース等）、乳化剤（例えば、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル等）、アミノ酸（例えば、ＤＬ−アラニン、Ｌ-アルギニン、塩酸Ｌ-リジン等）、ビタミン（例えば、Ｌ-アスコルビン酸、β−カロチン、酢酸ｄｌ−α−トコフェロール等）、ミネラル（例えば、塩化カリウム、クエン酸鉄、酸化マグネシウム等）、色素（例えばアスタキサンチン、カンタキサンチン等）、酵素（例えばアミラーゼ、フィターゼ、リパーゼ等）、有機酸（ギ酸、酢酸、乳酸等）が挙げられるが、これらに限定されない。 The method for adding coenzyme Q to the feed is not particularly limited. Coenzyme Q may be added directly to the feed, and if necessary, coenzyme Q may be mixed with the feed additive and then added to the feed to obtain a coenzyme Q-containing feed. As feed additives, live bacteria agents (for example, Enterococcus, Bacillus, Bifidobacterium), antioxidants (for example, ethoxyne, dibutylhydroxytoluene, etc.), fungicides (for example, propionic acid, calcium propionate, etc.) , Binder (eg, sodium alginate, sodium caseinate, carboxymethyl cellulose, etc.), emulsifier (eg, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, etc.), amino acid (eg, DL-alanine, L-arginine, hydrochloric acid) L-lysine etc.), vitamins (eg L-ascorbic acid, β-carotene, dl-α-tocopherol acetate etc.), minerals (eg potassium chloride, iron citrate, magnesium oxide etc.), pigments (eg astaxanthin, canta Xanthine), enzymes (eg Amylase, phytase, lipase, etc.) and organic acids (formic acid, acetic acid, lactic acid, etc.), but are not limited thereto.
飼料に含有させる補酵素Ｑの量は、投与の目的、対象動物の種類、体重、月齢、供与飼料、飼育環境等によって異なるが、飼料中の濃度は、家畜又は家禽の良好な成長を確保する観点から１ｐｐｍ以上であることが好ましく、より好ましくは５ｐｐｍ以上であり、より好ましくは１０ｐｐｍ以上であり、さらに好ましくは２０ｐｐｍ以上であり、さらに好ましくは４０ｐｐｍ以上であり、とりわけ好ましくは１００ｐｐｍ以上である。 The amount of coenzyme Q contained in the feed varies depending on the purpose of administration, the type of target animal, body weight, age, donated feed, breeding environment, etc., but the concentration in the feed ensures good growth of livestock or poultry. From the viewpoint, it is preferably 1 ppm or more, more preferably 5 ppm or more, more preferably 10 ppm or more, further preferably 20 ppm or more, further preferably 40 ppm or more, and particularly preferably 100 ppm or more.
また、一日当たりの補酵素Ｑの投与量は、投与の目的、対象動物の種類、体重、月齢、供与飼料、飼育環境等によって異なるが、家畜又は家禽の良好な成長を確保する観点から、体重１ｋｇあたり０．１ｍｇ／ｋｇ以上であることが好ましく、より好ましくは１ｍｇ／ｋｇ以上、更に好ましくは５ｍｇ／ｋｇ以上である。 The daily dose of coenzyme Q varies depending on the purpose of administration, the type of target animal, body weight, age, feed, breeding environment, etc., but from the viewpoint of ensuring good growth of livestock or poultry, It is preferably 0.1 mg / kg or more per kg, more preferably 1 mg / kg or more, still more preferably 5 mg / kg or more.
本発明の飼料において、補酵素Ｑの含有量は、抗生物質及び抗菌剤の使用量を低減した上で、家畜又は家禽の良好な成長を確保する観点から、抗生物質及び抗菌剤の含有量の合計３重量部に対して、２重量部以上であることが好ましく、より好ましくは１０重量部以上であり、より好ましくは３０重量部以上であり、さらに好ましくは１００重量部以上である。 In the feed of the present invention, the content of the coenzyme Q is the content of the antibiotic and antibacterial agent from the viewpoint of ensuring good growth of livestock or poultry after reducing the amount of antibiotic and antibacterial agent used. The total amount is 3 parts by weight, preferably 2 parts by weight or more, more preferably 10 parts by weight or more, more preferably 30 parts by weight or more, and still more preferably 100 parts by weight or more.
本発明によれば、飼料中に補酵素Ｑを添加することで、飼料中の抗生物質及び抗菌剤の濃度を通常使用される濃度よりも低くする、あるいは、まったく使用しないことが可能であり、補酵素Ｑを抗生物質及び抗菌剤の代替とすることができる。 According to the present invention, by adding coenzyme Q to the feed, it is possible to make the concentrations of antibiotics and antibacterial agents in the feed lower than those normally used, or not at all, Coenzyme Q can be substituted for antibiotics and antibacterial agents.
本発明の飼料の給餌対象動物は豚、牛、羊等の家畜、産卵鶏、ブロイラー、鶉等の家禽、犬、猫、馬等のペット動物が挙げられるがこれらに限定されない。 Examples of the animal to be fed with the feed of the present invention include, but are not limited to, livestock such as pigs, cows and sheep, poultry such as laying hens, broilers and rabbits, and pet animals such as dogs, cats and horses.
本発明にかかる飼料を家畜、又は家禽に摂取させる期間としては、補酵素Ｑの量や摂取の目的、対象動物の種類、体重、月齢、供与飼料、飼育環境等によって異なるが、一般的に４週間以上であることが好ましく、８週間以上がより好ましい。更に好ましくは１２週間以上である。 The period during which the feed according to the present invention is ingested by livestock or poultry varies depending on the amount of coenzyme Q, the purpose of ingestion, the type of target animal, body weight, age, feed, breeding environment, etc. Preferably it is a week or more, more preferably 8 weeks or more. More preferably, it is 12 weeks or more.
本発明にかかる飼料を家畜、又は家禽に摂取させる時期は、抗生物質及び抗菌剤の飼料への添加が認められている時期が好ましく、例えば産卵鶏の場合は、１０週齢までの時期であり、肉用鶏の場合は、と殺の７日前までの時期であり、豚の場合は体重が７０ｋｇとなるまでの時期であり、乳用牛の場合は育成期である。また、飼料中に抗生物質及び抗菌剤を全く含まない場合には、飼料への抗生物質及び抗菌剤の添加が禁止されている期間中、例えば産卵鶏では１０週以降、豚では体重７０ｋｇ以上出荷までの時期に、本発明の飼料を摂取させることが可能であり、該時期における感染症発生リスクを低下させて成長を促進できる点で好ましい。さらに、繁殖用家畜・家禽を対象とする場合は、当該家畜・家禽の生涯すべての期間、あるいは任意の特定の期間に摂取させることができる。 The period when the feed according to the present invention is ingested by livestock or poultry is preferably the period when the addition of antibiotics and antibacterial agents to the feed is permitted. For example, in the case of laying hens, the period is up to 10 weeks of age. In the case of beef chickens, it is the period up to 7 days before the killing, in the case of pigs it is the period until the weight reaches 70 kg, and in the case of dairy cattle it is the breeding period. If the feed does not contain antibiotics and antibacterial agents at all, during the period when the addition of antibiotics and antibacterial agents to the feed is prohibited, for example, after 10 weeks for laying hens, weigh 70 kg or more for pigs. It is possible to ingest the feed of the present invention at a time up to this point, which is preferable in that it can reduce the risk of developing an infection at that time and promote growth. Furthermore, in the case of targeting livestock and poultry for breeding, it can be ingested during the entire life of the livestock and poultry or any specific period.
本発明にかかる飼料を家畜又は家禽に給餌することにより、家畜又は家禽の腸内細菌叢を改善することができる。本発明における腸内細菌叢の改善とは、腸内において生体に対し悪影響を及ぼす菌（有害細菌）が減少することを意味し、例えば下痢などの症状の抑制が含まれる。有害細菌としては、下痢原性大腸菌（腸管毒素原性大腸菌、腸管病原性大腸菌、腸管組織侵入性大腸菌、毒血症由来大腸菌、敗血症由来大腸菌）、豚赤痢菌、食中毒性サルモネラ菌（豚コレラ菌、豚チフス菌、ネズミチフス菌）などが挙げられる。 By feeding the feed according to the present invention to livestock or poultry, the intestinal bacterial flora of livestock or poultry can be improved. The improvement of the intestinal microflora in the present invention means that bacteria (harmful bacteria) that adversely affect the living body in the intestine are reduced, and includes, for example, suppression of symptoms such as diarrhea. Examples of harmful bacteria include diarrheagenic Escherichia coli (enterotoxigenic Escherichia coli, enteropathogenic Escherichia coli, intestinal tissue invasive Escherichia coli, toxemia-derived Escherichia coli, septic-derived Escherichia coli, swine dysentery, food-toxic Salmonella (pig cholera, Swine typhoid bacteria, Salmonella typhimurium) and the like.
本発明にかかる家畜又は家禽の生産方法は、本発明にかかる飼料を家畜又は家禽に給餌することを特徴とする。
本発明にかかる飼料は、家畜又は家禽の腸内の有害細菌を減少させ、腸内環境を整え、下痢などの症状を抑制することなどにより、飼料効率を向上させる効果があり、有害細菌による細菌性疾患の予防に役立つ。
The method for producing livestock or poultry according to the present invention is characterized in that the feed according to the present invention is fed to livestock or poultry.
The feed according to the present invention has an effect of improving feed efficiency by reducing harmful bacteria in the intestines of livestock or poultry, adjusting the intestinal environment, and suppressing symptoms such as diarrhea. Helps prevent sexually transmitted diseases.
以下に実施例を揚げて本発明を更に詳しく説明するが、本発明はこれら実施例のみに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
実施例１
補酵素Ｑ１０が子豚の成長期における腸内環境を改善する効果について試験した。
哺乳期（体重約１０ｋｇ〜３０ｋｇ）の三元交雑種（ＬＷＤ・ＷＬＤ）子豚を各区６頭（雌雄各３頭）用意し、以下の飼料を与えた。即ち、無薬区には抗生物質及び抗菌剤を含まない豚産肉能力検定用飼料（ＴＤＮ７４．５％：無薬飼料）を、有薬区には無薬飼料に抗生物質及び抗菌剤としてノシヘプタイド５ｐｐｍ及びクエン酸モランテル３０ｐｐｍを添加した飼料を、補酵素Ｑ１０区には上記無薬飼料に補酵素Ｑ１０（株式会社カネカ製コエンザイムＱ１０）を２０ｐｐｍ又は４０ｐｐｍ添加した飼料を与えた。
観察項目は増体重、飼料要求率及び糞便内細菌数（補酵素Ｑ１０区は４０ｐｐｍ添加区のみ）とした。
Example 1
The effect of coenzyme Q10 on improving the intestinal environment during the growth period of piglets was tested.
Six ternary crossbred (LWD / WLD) piglets in the nursing period (body weight of about 10 kg to 30 kg) were prepared in each group (3 males and 3 females), and the following feeds were given. In other words, the no drug zone contains a feed for testing pork meat capacity that does not contain antibiotics and antibacterial agents (TDN 74.5%: no drug feed). The feed to which 5 ppm and 30 ppm of morantel citrate were added, and the feed obtained by adding 20 ppm or 40 ppm of coenzyme Q10 (Coenzyme Q10 manufactured by Kaneka Corporation) to the above-mentioned non-medicine feed was given to the coenzyme Q10 section.
Observed items were weight gain, feed demand rate, and number of bacteria in feces (coenzyme Q10 was only 40 ppm added).
（増体重）
観察開始時、及び終了時に子豚の体重を計測し、観察期間中の１頭あたりの増加体重（平均値）を期間増体重、１日あたりの１頭あたりの増加体重（平均値）を日増体重とした。
（飼料要求率）
（観察期間中に子豚が摂取した飼料の総量（ｋｇ）／期間増体重（ｋｇ））を飼料要求率とした。
（糞便内細菌数）
各細菌について、下記の条件で測定した。
(Weight gain)
Measure the weight of the piglets at the start and end of the observation, and increase the weight (average value) per head during the observation period during the observation period and increase the weight per head (average value) per day Increased weight.
(Feed demand rate)
(The total amount of feed (kg) / period weight gain (kg) consumed by piglets during the observation period) was defined as the feed request rate.
(Number of bacteria in feces)
Each bacterium was measured under the following conditions.
表２に増体重の結果を示した。補酵素Ｑ１０区の期間増体重及び日増体重は無薬区よりも明らかに高い値を示した。
表３に飼料要求率の結果を示した。補酵素Ｑ１０区は有薬区とほぼ同程度の値を示し、無薬区よりも明らかに低い値を示した。
表４及び図１に糞便内細菌数の結果を示した。補酵素Ｑ１０区では有薬区と同様に、無薬区と比べて腸内細菌科の細菌数及び大腸菌数が明らかに低い値を示した。
Table 2 shows the results of weight gain. The period weight gain and daily weight gain in the coenzyme Q10 group were clearly higher than those in the no drug group.
Table 3 shows the results of the feed request rate. The coenzyme Q10 group showed almost the same value as the drug group, and was clearly lower than the no drug group.
Table 4 and FIG. 1 show the results of the number of bacteria in the feces. In the coenzyme Q10 group, the number of bacteria in the Enterobacteriaceae family and the number of Escherichia coli were clearly lower than in the drugless group, as in the drug-treated group.
この結果は抗生物質及び抗菌剤を全く、もしくは、ほとんど含まず、かつ、補酵素Ｑ１０を含む家畜又は家禽用飼料が、通常使用される濃度の抗生物質及び抗菌剤を含む飼料と同様に腸内の有害細菌を減少させ、飼料効率を向上させる効果があり、細菌性疾患予防に役立つことを示している。また、本発明に係る家畜又は家禽用飼料は抗生物質及び抗菌剤とは異なり、耐性菌発現の恐れがない。 This result shows that livestock or poultry feed containing no or almost no antibiotics and antibacterial agents and containing coenzyme Q10 is enteric in the same manner as feeds containing antibiotics and antibacterial agents at the concentrations normally used. This has the effect of reducing harmful bacteria and improving feed efficiency, and helps prevent bacterial diseases. Further, the livestock or poultry feed according to the present invention has no fear of developing resistant bacteria, unlike antibiotics and antibacterial agents.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010053646A JP2011182748A (en) | 2010-03-10 | 2010-03-10 | Feed for livestock or poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010053646A JP2011182748A (en) | 2010-03-10 | 2010-03-10 | Feed for livestock or poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011182748A true JP2011182748A (en) | 2011-09-22 |
Family
ID=44789775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010053646A Pending JP2011182748A (en) | 2010-03-10 | 2010-03-10 | Feed for livestock or poultry |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2011182748A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016024344A1 (en) * | 2014-08-13 | 2016-02-18 | 日清ファルマ株式会社 | Livestock production method and livestock-growth promoting method |
| JP5868848B2 (en) * | 2010-05-21 | 2016-02-24 | 株式会社カネカ | Pig feed and its feeding method |
| JP2022134560A (en) * | 2021-03-03 | 2022-09-15 | 全国農業協同組合連合会 | Method for softening beef texture |
-
2010
- 2010-03-10 JP JP2010053646A patent/JP2011182748A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5868848B2 (en) * | 2010-05-21 | 2016-02-24 | 株式会社カネカ | Pig feed and its feeding method |
| WO2016024344A1 (en) * | 2014-08-13 | 2016-02-18 | 日清ファルマ株式会社 | Livestock production method and livestock-growth promoting method |
| JPWO2016024344A1 (en) * | 2014-08-13 | 2017-05-18 | 日清ファルマ株式会社 | Method for producing livestock and method for promoting growth of livestock |
| JP2022134560A (en) * | 2021-03-03 | 2022-09-15 | 全国農業協同組合連合会 | Method for softening beef texture |
| JP7387183B2 (en) | 2021-03-03 | 2023-11-28 | 全国農業協同組合連合会 | How to soften beef meat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hajati | Application of organic acids in poultry nutrition | |
| Hofacre et al. | Antimicrobial drug use in poultry | |
| JP6012111B2 (en) | Animal feed additives | |
| US11517551B2 (en) | Lactylates for the prevention and treatment of infections caused by gram-positive bacteria in animals | |
| CN101331915B (en) | Animal feed composition | |
| EP0104630B1 (en) | Animal growth promotant and method of use for animal growth | |
| WO2001028551A1 (en) | Agents for promoting fattening of animals and method of promoting fattening | |
| JP2011182748A (en) | Feed for livestock or poultry | |
| Ishfaq et al. | Effect of Acipure (feed acidifier) on the growth performance, mortality and gut pH of broiler chickens. | |
| EP3838347B1 (en) | Evernimicin for treating diseases like necrotic enteritis | |
| Kan et al. | Feed additives: do they add to animal welfare? An evaluation | |
| US20150202209A1 (en) | Method of enhancing the performance of broiler chickens | |
| WO1999032144A1 (en) | Method for preventing/remedying mastitis | |
| JPS63238020A (en) | Bacillus polymyxa containing drug for livestock administration | |
| JP5893406B2 (en) | Use of azaperone to reduce antibiotic use | |
| CN102178062A (en) | Application of glyceroltriacetate as feed acidating agent | |
| ES2401877T3 (en) | Use of sulfadimidine amides for the treatment of intestinal diseases in veterinary science | |
| JPH06701B2 (en) | Veterinary composition | |
| JPH0291026A (en) | Method for preventing and treating liver tumor of animal and animal feed composition | |
| JPH06128163A (en) | Agent for preventing or treating fish streptococcosis with mixed ingredients | |
| JPH03264526A (en) | Preventive or therapeutic agent for streptococcosis in fish | |
| JPH08245396A (en) | Agent for anticholesterol |